The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?

Although all patients in the intention-to-treat populations of Study19, ARIEL3, and NOVA benefited from the use of PARPi maintenance therapy versus placebo in this setting, an evident trend emerged where the magnitude of PFS benefit differed incrementally between HRD-negative, HRD-positive, and BRCA1/2 -mutant subgroups ( Table 1 ).

also in 268 other papers